Anti-inflammatory agents as cancer therapeutics.
作者： Khosrow Kashfi
DOI: 10.1016/S1054-3589(08)57002-5
关键词:
摘要: Abstract Cancer prevention sometimes referred to as tertiary or chemoprevention makes use of specific xenobiotics drugs prevent, delay, retard the development cancer. Over last two decades so cancer has made significant strides. For example, lung through smoking cessation; cervical regular Pap smear tests; colon screening colonoscopy; and prostate reductions by prostate-specific antigen measurements in conjunction with examinations. The seminal epidemiological observation that nonsteroidal anti-inflammatory (NSAIDs) prevent other cancers provided impetus develop novel approaches against To end, a number “designer drugs” have been synthesized are different stages development, evaluation, deployment. Some include cyclooxygenase-2-specific inhibitors (coxibs), nitric oxide-releasing NSAIDs (NO-NSAIDs NONO-NSAIDs), hydrogen sulfide-releasing NSAIDs, modulators lipoxygenase pathway, prostanoid receptor blockers, chemokine antagonists. In addition these agents, there also host naturally occurring compounds/micronutrients chemopreventive properties. This chapter reviews classes compounds, their utility mechanism(s) action background mediators link inflammation
elsevier.com
sci-hub.se 参考文章(321)
MARIO I Ortiz, GILBERTO Castañeda-Hernández, RODOLFO Rosas, GC Vidal-Cantu, V Granados-Soto, Evidence for a new mechanism of action of diclofenac: activation of K+ channels. Proceedings of the Western Pharmacology Society. ,vol. 44, pp. 19- 21 ,(2001)
J J Reid, ABT-761 (Abbott). Current opinion in investigational drugs. ,vol. 2, pp. 68- 71 ,(2001)
F. R. Balkwill, J. Hadley, G. W. H. Stamp, R. P. M. Negus, Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. American Journal of Pathology. ,vol. 150, pp. 1723- 1734 ,(1997)
Levine L, Goldman Is, Rigas B, Altered eicosanoid levels in human colon cancer. Journal of Laboratory and Clinical Medicine. ,vol. 122, pp. 518- 523 ,(1993)
J L Wallace, C M Hogaboam, A D Befus, Modulation of rat mast cell reactivity by IL-1 beta. Divergent effects on nitric oxide and platelet-activating factor release. Journal of Immunology. ,vol. 151, pp. 3767- 3774 ,(1993)
Anna Tesei, Paola Ulivi, Francesco Fabbri, Marco Rosetti, Carlo Leonetti, Marco Scarsella, Gabriella Zupi, Dino Amadori, Manlio Bolla, Wainer Zoli, In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines Journal of Translational Medicine. ,vol. 3, pp. 7- 7 ,(2005) , 10.1186/1479-5876-3-7
Masahiro Sonoshita, Kazuaki Takaku, Nobuya Sasaki, Yukihiko Sugimoto, Fumitaka Ushikubi, Shuh Narumiya, Masanobu Oshima, Makoto M. Taketo, Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice Nature Medicine. ,vol. 7, pp. 1048- 1051 ,(2001) , 10.1038/NM0901-1048
J.-W. Soh, B. Weinstein, Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Progress in Experimental Tumor Research. ,vol. 37, pp. 261- 283 ,(2003) , 10.1159/000071377
Gerald P. Morris, Paul L. Beck, Margaret S. Herridge, William T. Depew, Myron R. Szewczuk, John L. Wallace, Hapten-Induced Model of Chronic Inflammation and Ulceration in the Rat Colon Gastroenterology. ,vol. 96, pp. 795- 803 ,(1989) , 10.1016/S0016-5085(89)80079-4
A Ben-Baruch, Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor–microenvironment interactions Breast Cancer Research. ,vol. 5, pp. 31- 36 ,(2002) , 10.1186/BCR554